Skip to content

MBX Biosciences, Inc. MBX Q1 2025 earnings

Reported May 12, 2025 · Before market open

Next report

Aug 6, 2026 (in a month)
EPS estimate-$0.68

Financials

Q1 2025

Income statement

See full
Operating income-$26.5M-99.3%
Net income-$23.9M-93.6%
EPS (diluted)-$0.71+93.1%

Balance sheet

See full
Cash & equivalents$29.9M
Total debt$130.0K
Total equity$235.4M+383%
Total assets$245.9M

Cash flow

See full
Operating cash flow-$22.7M-112%
CapEx$30.0K-89.0%
Free cash flow-$22.7M-107%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$246.67M
Enterprise value$216.9M

Returns & leverage

See full
Debt / equity
Current ratio23.3×

Versus estimates

Ask the moment MBX Biosciences, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did MBX Biosciences, Inc. report Q1 2025 earnings?
MBX Biosciences, Inc. (MBX) reported Q1 2025 earnings on May 12, 2025 before market open.
What were MBX Biosciences, Inc.'s Q1 2025 revenue and EPS?
MBX Biosciences, Inc. reported diluted EPS of $-0.71 for Q1 2025.
Did MBX Biosciences, Inc. beat estimates in Q1 2025?
EPS beat the consensus estimate of $-0.81 by $0.10.
How did MBX Biosciences, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 93.8% from $-11.47.
Where can I find MBX Biosciences, Inc.'s Q1 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-068602) directly on SEC EDGAR. The filing index links above go to sec.gov.